Autolus Therapeutics Receives PRIME Designation From EMA For AUTO1 For The treatment Of Adult ALL
Autolus Therapeutics Receives PRIME Designation From EMA For AUTO1 For The treatment Of Adult ALL
Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has received PRIority MEdicines (PRIME) designation from the European Medicines Agency (EMA) for AUTO1, the company's CAR T cell therapy being investigated in the ongoing FELIX Phase 1b/2 study in relapsed / refractory (r/r) adult B-Acute Lymphocytic Leukemia (ALL).
Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has received PRIority MEdicines (PRIME) designation from the European Medicines Agency (EMA) for AUTO1, the company's CAR T cell therapy being investigated in the ongoing FELIX Phase 1b/2 study in relapsed / refractory (r/r) adult B-Acute Lymphocytic Leukemia (ALL).
開發下一代程序化T細胞療法的臨牀階段生物製藥公司Autolus Treeutics plc(納斯達克市場代碼：AUTL)今天宣佈，它已獲得歐洲藥品管理局(EMA)指定的治療AUTO1的優先藥物(PRIME)，該公司的CAR T細胞療法正在進行的Felix 1b/2期復發/難治性成人B急性淋巴細胞白血病(ALL)研究中接受調查。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧